SCHEMBL10243878

SCHEMBL10243878

O=C(c1ccc2c(c1)OCCO2)N1C2CCC1CC(c1ccc(F)c(Cl)c1)C2

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ LMNA P02545 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MAOB P27338 6/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ MGLL Q99685 4/20 0.43
▸ TSHR P16473 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ PKLR P30613 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243843 0.90 LMNA (0.54) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL17350919 0.90 LMNA (0.54) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL10243882 0.88 MAOB (0.51) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL17350779 0.86 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL10243800 0.86 ALDH1A1 (0.53) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL10243946 0.83 ALDH1A1 (0.47) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL2683635 0.82 TSHR (0.48) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL10243945 0.82 TSHR (0.48) ALDH1A1LMNAHSD17B10NPC1RAB9A
SCHEMBL10243619 0.82 TSHR (0.48) ALDH1A1LMNAHSD17B10MAOBNPC1
SCHEMBL17350804 0.82 TSHR (0.48) ALDH1A1LMNAHSD17B10NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2318403-B1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use BOEHRINGER INGELHEIM INT (DE) 2015-12-23 — — EP disclosed
EP-2318403-B1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use BOEHRINGER INGELHEIM INT (DE) 2015-12-23 — — EP disclosed
US-20120115853-A1 Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-10 — — US disclosed
WO-2010023161-A1 ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115853-A1 Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use HSD11B1, HSD11B2, HSD17B1 ALDH1A1 141/4885LMNA 2595/4885HSD17B10 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback